4-aminopyridine improves evoked potentials and ambulation in the taiep rat: A model of hypomyelination with atrophy of basal ganglia and cerebellum

PLoS One. 2024 Mar 1;19(3):e0298208. doi: 10.1371/journal.pone.0298208. eCollection 2024.

Abstract

The taiep rat is a tubulin mutant with an early hypomyelination followed by progressive demyelination of the central nervous system due to a point mutation in the Tubb4a gene. It shows clinical, radiological, and pathological signs like those of the human leukodystrophy hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). Taiep rats had tremor, ataxia, immobility episodes, epilepsy, and paralysis; the acronym of these signs given the name to this autosomal recessive trait. The aim of this study was to analyze the characteristics of somatosensory evoked potentials (SSEPs) and motor evoked potentials (MEPs) in adult taiep rats and in a patient suffering from H-ABC. Additionally, we evaluated the effects of 4-aminopyridine (4-AP) on sensory responses and locomotion and finally, we compared myelin loss in the spinal cord of adult taiep and wild type (WT) rats using immunostaining. Our results showed delayed SSEPs in the upper and the absence of them in the lower extremities in a human patient. In taiep rats SSEPs had a delayed second negative evoked responses and were more susceptible to delayed responses with iterative stimulation with respect to WT. MEPs were produced by bipolar stimulation of the primary motor cortex generating a direct wave in WT rats followed by several indirect waves, but taiep rats had fused MEPs. Importantly, taiep SSEPs improved after systemic administration of 4-AP, a potassium channel blocker, and this drug induced an increase in the horizontal displacement measured in a novelty-induced locomotor test. In taiep subjects have a significant decrease in the immunostaining of myelin in the anterior and ventral funiculi of the lumbar spinal cord with respect to WT rats. In conclusion, evoked potentials are useful to evaluate myelin alterations in a leukodystrophy, which improved after systemic administration of 4-AP. Our results have a translational value because our findings have implications in future medical trials for H-ABC patients or with other leukodystrophies.

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Animals
  • Atrophy
  • Basal Ganglia
  • Cerebellum
  • Demyelinating Diseases* / drug therapy
  • Demyelinating Diseases* / genetics
  • Evoked Potentials
  • Hereditary Central Nervous System Demyelinating Diseases*
  • Humans
  • Rats
  • Rats, Mutant Strains
  • Walking
  • White Matter*

Substances

  • 4-Aminopyridine

Supplementary concepts

  • Leukodystrophy, Hypomyelinating, 6

Grants and funding

First: Consejo Nacional de Ciencia y Tecnología (CONACYT) through Programas Nacionales Estratégicos (PRONACES) number 194171 being the recipient Dr. Victor Hugo Hernandez (VHH). Second: Vicerrectoría de Investigación y Estudios de Posgrado (VIEP) de la Benemérita Universidad Autónoma de Puebla (BUAP) grant to Cuerpo Académico en Neuroendocrinología (CA-BUAP-288) 2023 to Jose R. Eguibar and Carmen Cortes.